Analyst Reco. Nuvalent, Inc.

Equities

NUVL

US6707031075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
66.86 ^USD	+1.20%		+6.53%	-9.15%

Apr. 17	Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	MT
Apr. 17	Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing	Apr. 17	MT
Jefferies Initiates Nuvalent With Buy Rating, $97 Price Target	Apr. 17	MT
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing	Apr. 10	MT
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing	Apr. 01	MT
Leerink Partners Upgrades Nuvalent to Outperform From Market Perform, Raises Price Target to $110 From $69	Apr. 01	MT
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing	Mar. 25	MT
BMO Capital Raises Price Target on Nuvalent to $102 From $93, Maintains Outperform Rating	Feb. 28	MT
Baird Initiates Nuvalent With Outperform Rating, Price Target is $105	Feb. 23	MT
Wedbush Raises Nuvalent's Price Target to $99 From $82, Maintains Outperform Rating	Feb. 12	MT
Wedbush Raises Nuvalent's PT to $82 From $74 After Announced 3-Year Plan to Place At Least One Lead Asset on Market by 2026; Keeps Outperform Rating	Jan. 08	MT
BMO Capital Adjusts Nuvalent Price Target to $79 From $73, Maintains Outperform Rating	23-10-18	MT
Wedbush Raises Nuvalent Price Target to $74 From $65, Maintains Outperform Rating	23-10-13	MT
JPMorgan Adjusts Price Target on Nuvalent to $68 From $51, Maintains Overweight Rating	23-10-05	MT
BMO Capital Adjusts Price Target on Nuvalent to $73 From $52, Keeps Outperform Rating	23-10-05	MT
Wedbush Raises Nuvalent's PT to $65 From $53 After Positive Phase 1 Trial Data on NVL-655 in Advanced ALK-Positive Lung Cancer; Keeps Outperform Rating	23-10-05	MT
Nuvalent Shares Rise After Stifel Starts Coverage With Buy Rating	23-09-27	MT
Stifel Initiates Nuvalent With Buy Rating	23-09-27	MT
SVB Securities Initiates Nuvalent With Market Perform Rating, $42 Price Target	23-08-08	MT
Guggenheim Starts Nuvalent at Buy With $56 Price Target	23-07-24	MT
JPMorgan Chase Raises Price Target on Nuvalent to $48 From $37, Maintains Overweight Rating	23-06-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Nuvalent, Inc.

Equities

NUVL

US6707031075

Analyst Reco.

Filters